Prostate cancer remains the most common cancer among men in the UK, with over 52,000 new cases diagnosed each year. Despite its prevalence, there is no national screening programme for the disease, a position maintained by the UK National Screening Committee (UK NSC). This decision is based on a careful weighing of the potential benefits of early detection against the significant harms associated with current screening methods, primarily the Prostate Specific Antigen (PSA) blood test.
The PSA test measures the level of PSA in a man's blood, which can be elevated in the presence of prostate cancer. However, high PSA levels can also be caused by other conditions, such as an enlarged prostate or infection. This lack of specificity means the test can lead to 'false positives', causing anxiety and potentially unnecessary further investigations, including biopsies, which carry their own risks. Conversely, some aggressive cancers may not cause a significant rise in PSA, leading to 'false negatives' and a false sense of security.
A major concern is the issue of overdiagnosis and overtreatment. Many prostate cancers grow very slowly and may never cause significant problems during a man's lifetime. Detecting and treating these low-risk cancers can lead to side effects such as incontinence and erectile dysfunction, without providing a clear benefit to the patient's lifespan or quality of life. The UK NSC's stance reflects a commitment to ensuring that any screening programme introduced offers a clear net benefit to the population, where the benefits of early detection outweigh the potential harms of diagnosis and treatment.
Currently, men aged 50 and over in the UK have the option to request a PSA test from their General Practitioner (GP). This is known as 'informed choice'. Before undergoing the test, men are encouraged to have a thorough discussion with their GP about the potential advantages and disadvantages. This conversation should cover the limitations of the PSA test, the possibility of false positives or negatives, and the implications of subsequent diagnostic procedures and potential treatments.
Research into more accurate and less harmful screening methods is ongoing. Scientists are exploring new biomarkers, imaging techniques, and genetic tests that could potentially identify aggressive cancers more reliably while reducing the detection of harmless ones. Until such advancements are robustly proven to offer a better balance of benefits over harms, the UK's approach to prostate cancer screening is likely to remain focused on informed individual choice rather than a population-wide programme.
For any concerns about prostate cancer or to discuss the PSA test, individuals should consult their GP or call NHS 111. Further information is also available from reputable health organisations.
Source: NHS, UK National Screening Committee